share_log

Femasys | 8-K: Femasys Announces Financial Results for Quarter Ended September 30, 2024, and Provides Corporate Update

SEC ·  Nov 12, 2024 14:33

Summary by Futu AI

Femasys reported Q3 2024 sales of $554,908, up 127.1% YoY, driven by initial commercialization of FemaSeed infertility treatment and increased FemVue sales. The company secured strategic partnerships with Boston IVF and distributors in Spain, with Spanish partnerships expected to generate over $1.3 million in the next year.R&D expenses increased 11.1% YoY to $2.3 million, while net loss widened to $5.4 million ($0.24 per share) from $4.0 million ($0.26 per share) in Q3 2023. The company received FDA 510(k) clearance for FemChec and CE Mark certification for FemVue MINI during the quarter.As of September 30, 2024, cash and cash equivalents stood at $7.6 million, expected to fund operations into July 2025. The company's accumulated deficit reached $122.1 million, with management focused on expanding commercial partnerships and advancing its women's health product portfolio.
Femasys reported Q3 2024 sales of $554,908, up 127.1% YoY, driven by initial commercialization of FemaSeed infertility treatment and increased FemVue sales. The company secured strategic partnerships with Boston IVF and distributors in Spain, with Spanish partnerships expected to generate over $1.3 million in the next year.R&D expenses increased 11.1% YoY to $2.3 million, while net loss widened to $5.4 million ($0.24 per share) from $4.0 million ($0.26 per share) in Q3 2023. The company received FDA 510(k) clearance for FemChec and CE Mark certification for FemVue MINI during the quarter.As of September 30, 2024, cash and cash equivalents stood at $7.6 million, expected to fund operations into July 2025. The company's accumulated deficit reached $122.1 million, with management focused on expanding commercial partnerships and advancing its women's health product portfolio.

The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Comment Comment · Views 282

Recommended